Naganawa S, Ginsberg H N, Glickman R M, Ginsburg G S
Department of Medicine, Beth Israel Hospital, Boston, Massachusetts 02215, USA.
J Clin Invest. 1997 Apr 15;99(8):1958-65. doi: 10.1172/JCI119363.
To understand the factors contributing to the synthesis of human apolipoprotein AI (apoAI), relative apoAI synthesis was measured from endoscopic biopsy samples obtained from 18 healthy volunteers. The relative amount of apoAI synthesis was directly correlated with steady state intestinal apoAI mRNA levels and a 10-fold within-group variability was observed. Analysis of genomic DNA from the subjects revealed five polymorphic sites which defined two haplotypes in the intestinal enhancer region of the apoAI gene located upstream of the apolipoprotein CIII gene transcriptional start site (+ 1): (-641 C to A, -630 G to A, -625 T to deletion, -482 C to T, and -455 T to C). The population frequencies of the wild-type and mutant alleles were 0.53 and 0.44, respectively. Mean steady state apoAI mRNA levels and mean relative apoAI synthesis were 49 and 37% lower, respectively, in homozygotes for the mutant allele and 28 and 41% lower, respectively, in heterozygotes than in homozygotes for the wild-type allele (P < 0.05 for both). Site-directed mutants of apoAI gene promoter/reporter constructs containing the above mutations were transfected into Caco-2 cells and showed a 46% decrease in transcriptional activity compared with the wild type (P < 0.001); however, no significant differences were observed in HepG2 cells. Electrophoretic mobility shift assays showed that the mutated sequences from -655 to -610 bound Caco-2 cell nuclear protein(s) while the wild type did not. These results indicate that intestinal apoAI gene transcription and protein synthesis are genetically determined and are reduced in the presence of common mutations which induced binding of nuclear protein(s), possibly a transcriptional repressor.
为了解影响人载脂蛋白AI(apoAI)合成的因素,我们检测了18名健康志愿者内镜活检样本中的相对apoAI合成量。apoAI合成的相对量与稳态肠道apoAI mRNA水平直接相关,且观察到组内存在10倍的变异性。对受试者的基因组DNA分析发现了五个多态性位点,这些位点在载脂蛋白CIII基因转录起始位点(+1)上游的apoAI基因肠道增强子区域定义了两种单倍型:(-641 C突变为A,-630 G突变为A,-625 T缺失,-482 C突变为T,以及-455 T突变为C)。野生型和突变型等位基因的群体频率分别为0.53和0.44。与野生型等位基因纯合子相比,突变型等位基因纯合子的平均稳态apoAI mRNA水平和平均相对apoAI合成量分别降低了49%和37%,杂合子分别降低了28%和41%(两者P均<0.05)。将含有上述突变的apoAI基因启动子/报告基因构建体的定点突变体转染到Caco-2细胞中,与野生型相比,转录活性降低了46%(P<0.001);然而,在HepG2细胞中未观察到显著差异。电泳迁移率变动分析表明,从-655到-610的突变序列能结合Caco-2细胞核蛋白,而野生型则不能。这些结果表明,肠道apoAI基因转录和蛋白质合成是由基因决定的,在存在诱导核蛋白(可能是转录抑制因子)结合的常见突变时会减少。